Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Teva presented new clinical and real-world data at Psych Congress 2026 in New Orleans, supporting durable disease control for its investigational once-monthly olanzapine injectable, olanzapine LAI. FDA action date for olanzapine LAI is expected in Q4 2026; the product remains unapproved.
Teva says it will present new post hoc data for olanzapine LAI (TEV-'749) from its SOLARIS Phase 3 trial, focused on stabilization and long-term efficacy for schizophrenia treatment in adults.